文献

J-GLOBAL ID：202002283184296445   整理番号：20A2797796

多能性幹細胞由来ヒト肺肺胞2型細胞のSARS-CoV-2感染は急速な上皮内因性炎症反応を誘発する【JST・京大機械翻訳】

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

著者 (45件)： Huang Jessie (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Huang Jessie (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Hume Adam J. (Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA) ,  Hume Adam J. (National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA) ,  Abo Kristine M. (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Abo Kristine M. (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Werder Rhiannon B. (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Werder Rhiannon B. (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Werder Rhiannon B. (QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  Villacorta-Martin Carlos (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Alysandratos Konstantinos-Dionysios (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Alysandratos Konstantinos-Dionysios (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Beermann Mary Lou (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Beermann Mary Lou (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Simone-Roach Chantelle (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Simone-Roach Chantelle (Pulmonary and Respiratory Diseases, Boston Children’s Hospital, Boston, MA 02115, USA) ,  Lindstrom-Vautrin Jonathan (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Olejnik Judith (Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA) ,  Olejnik Judith (National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA) ,  Suder Ellen L. (Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA) ,  Suder Ellen L. (National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA) ,  Bullitt Esther (Department of Physiology & Biophysics, Boston University, Boston, MA 02118, USA) ,  Hinds Anne (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Sharma Arjun (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Sharma Arjun (Center for Thrombosis and Hemostasis, University Medical Center Mainz, 55131 Mainz, Germany) ,  Bosmann Markus (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Bosmann Markus (Center for Thrombosis and Hemostasis, University Medical Center Mainz, 55131 Mainz, Germany) ,  Bosmann Markus (Research Center for Immunotherapy (FZI), University Medical Center, University of Mainz, Mainz, Germany) ,  Bosmann Markus (Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118, USA) ,  Wang Ruobing (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Wang Ruobing (Pulmonary and Respiratory Diseases, Boston Children’s Hospital, Boston, MA 02115, USA) ,  Wang Ruobing (Department of Medicine, Harvard Medical School, Boston, MA 02115, USA) ,  Hawkins Finn (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Hawkins Finn (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Burks Eric J. (Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118, USA) ,  Saeed Mohsan (Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA) ,  Saeed Mohsan (National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA) ,  Saeed Mohsan (Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA) ,  Wilson Andrew A. (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Wilson Andrew A. (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Muehlberger Elke (Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA) ,  Muehlberger Elke (National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA) ,  Kotton Darrell N. (Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA) ,  Kotton Darrell N. (The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA) ,  Kotton Darrell N. (Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118, USA)
資料名： Cell Stem Cell  (Cell Stem Cell)
巻： 27  号： 6  ページ： 962-973.e7  発行年： 2020年 
JST資料番号： W3106A  ISSN： 1934-5909  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 重症COVID-19肺炎の特徴は,肺胞上皮型2細胞(AT2s)の肺肺胞の通性前駆細胞のSARS-CoV-2感染である。しかし,特に疾患の初期段階において,患者からこれらの細胞をアクセスできないことは,疾患開始の理解を制限する。ここでは,気-液界面培養に適応した誘導多能性幹細胞由来AT2を用いて,SARS-CoV-2による肺胞上皮の初期頂端感染をシミュレートするin vitroヒトモデルを提示する。NF-κBシグナル伝達のアップレギュレーションと成熟肺胞プログラムの消失を伴う炎症表現型へのシフトを特徴とする感染細胞での迅速なトランスクリプトーム変化を見出した。薬剤試験は,TMPRSS2プロテアーゼ阻害と同様に,レムデスビルの有効性を確認し,肺胞細胞におけるウイルス侵入に対し使用される推定機構を検証した。著者らのモデル系は,SARS-CoV-2感染に対する重要な肺標的細胞の細胞内因性応答を明らかにし,薬物開発を促進するはずである。Copyright 2020 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *炎症 ,  *上皮 ,  肺炎 ,  *肺胞 ,  ヒト ,  表現型 ,  ペプチド結合ヒドロラーゼ ,  細胞情報伝達 ,  アップレギュレーション ,  in vitro実験 ,  NFκB ,  トランスクリプトーム
準シソーラス用語： *内因性 ,  創薬 ,  *炎症反応 , 【Automatic Indexing@JST】

著者キーワード (8件)： SARS-CoV-2 ,  COVID-19 ,  肺胞上皮細胞 ,  肺胞2型細胞 ,  ヒト人工多能性幹細胞 ,  肺 ,  iPSC ,  炎症

分類 (4件)： ウイルス感染の生理と病原性  (EG04042Y) ,  細胞・組織培養法  (EA03040R) ,  呼吸器の基礎医学  (GI01020H) ,  細胞生理一般  (EF02010S)

タイトルに関連する用語 (11件)： 多能性幹細胞 ,  ヒト ,  肺 ,  肺胞 ,  細胞 ,  SARS-CoV-2 ,  感染 ,  上皮 ,  内因性 ,  炎症反応 ,  誘発